John Billimek1, Shaista Malik2, Dara H Sorkin3, Priel Schmalbach4, Quyen Ngo-Metzger3, Sheldon Greenfield3, Sherrie H Kaplan3. 1. Health Policy Research Institute, School of Medicine, University of California, Irvine, California; Department of Medicine, School of Medicine, University of California, Irvine, California. Electronic address: jbillime@uci.edu. 2. Division of Cardiology, Department of Medicine, School of Medicine, University of California, Irvine, California. 3. Health Policy Research Institute, School of Medicine, University of California, Irvine, California; Department of Medicine, School of Medicine, University of California, Irvine, California. 4. School of Social Ecology, University of California, Irvine, California; School of Medicine, University of California, Irvine, California.
Abstract
BACKGROUND: Gender differences in dyslipidemia are widely documented, but the contributors to these differences are not well understood. This study examines whether differences in quality of care, intensity of lipid-lowering medication regimen, and medication adherence can explain this disparity. METHODS: Secondary analysis of medical records data and questionnaires collected from adult patients with type 2 diabetes (n = 1,369) from seven outpatient clinics affiliated with an academic medical center as part of the Reducing Racial Disparities in Diabetes: Coached Care (R2D2C2) study. Primary outcome was low-density lipoprotein (LDL) cholesterol. FINDINGS: Women had higher LDL cholesterol levels than men (mean [SD], 101.2 [35.2] vs. 92.3 [33.0] mg/dL; p < .001), but were no less likely to receive recommended processes of diabetes care, to attain targets for glycemic control and blood pressure, or to be on intensive medication regimens. More women than men reported medication nonadherence related to cost (32.7% vs. 24.2%; p = .040) and related to side effects (47.2% vs. 36.8%; p = .024). For all patients, regimen intensity (p < .05) and nonadherence related to side effects (p < .01) were each associated with higher LDL cholesterol levels. The addition of a new lipid-lowering agent was associated with subsequent nonadherence related to side effects for women (p < .001), but not for men (p = .45; test for interaction p = .048). CONCLUSIONS: Despite comparable quality of diabetes care and regimen intensity for lipid management, women with diabetes experienced poorer lipid control than men. Medication nonadherence seemed to be a major contributor to dyslipidemia, particularly for women because of side effects associated with intensifying the lipid-lowering regimen.
BACKGROUND: Gender differences in dyslipidemia are widely documented, but the contributors to these differences are not well understood. This study examines whether differences in quality of care, intensity of lipid-lowering medication regimen, and medication adherence can explain this disparity. METHODS: Secondary analysis of medical records data and questionnaires collected from adult patients with type 2 diabetes (n = 1,369) from seven outpatient clinics affiliated with an academic medical center as part of the Reducing Racial Disparities in Diabetes: Coached Care (R2D2C2) study. Primary outcome was low-density lipoprotein (LDL) cholesterol. FINDINGS:Women had higher LDL cholesterol levels than men (mean [SD], 101.2 [35.2] vs. 92.3 [33.0] mg/dL; p < .001), but were no less likely to receive recommended processes of diabetes care, to attain targets for glycemic control and blood pressure, or to be on intensive medication regimens. More women than men reported medication nonadherence related to cost (32.7% vs. 24.2%; p = .040) and related to side effects (47.2% vs. 36.8%; p = .024). For all patients, regimen intensity (p < .05) and nonadherence related to side effects (p < .01) were each associated with higher LDL cholesterol levels. The addition of a new lipid-lowering agent was associated with subsequent nonadherence related to side effects for women (p < .001), but not for men (p = .45; test for interaction p = .048). CONCLUSIONS: Despite comparable quality of diabetes care and regimen intensity for lipid management, women with diabetes experienced poorer lipid control than men. Medication nonadherence seemed to be a major contributor to dyslipidemia, particularly for women because of side effects associated with intensifying the lipid-lowering regimen.
Authors: Erica L Brooks; Sarah Rosner Preis; Shih-Jen Hwang; Joanne M Murabito; Emelia J Benjamin; Margaret Kelly-Hayes; Paul Sorlie; Daniel Levy Journal: Am J Med Date: 2010-08 Impact factor: 4.965
Authors: Varsha G Vimalananda; Donald R Miller; Madhuri Palnati; Cindy L Christiansen; B Graeme Fincke Journal: Womens Health Issues Date: 2011 Jul-Aug
Authors: Carol J Homko; Linda Zamora; William P Santamore; Abul Kashem; Timothy McConnell; Alfred A Bove Journal: Diabetes Educ Date: 2010-04-01 Impact factor: 2.140
Authors: Jennifer Lewey; William H Shrank; Ashna D K Bowry; Elaine Kilabuk; Troyen A Brennan; Niteesh K Choudhry Journal: Am Heart J Date: 2013-03-26 Impact factor: 4.749
Authors: Shaista Malik; John Billimek; Sheldon Greenfield; Dara H Sorkin; Quyen Ngo-Metzger; Sherrie H Kaplan Journal: Med Care Date: 2013-02 Impact factor: 2.983
Authors: Corrine I Voils; Matthew L Maciejewski; Rick H Hoyle; Bryce B Reeve; Patrick Gallagher; Christopher L Bryson; William S Yancy Journal: Med Care Date: 2012-12 Impact factor: 2.983
Authors: Sherrie H Kaplan; John Billimek; Dara H Sorkin; Quyen Ngo-Metzger; Sheldon Greenfield Journal: J Gen Intern Med Date: 2013-10 Impact factor: 5.128
Authors: Varsha G Vimalananda; Donald R Miller; Timothy P Hofer; Robert G Holleman; Mandi L Klamerus; Eve A Kerr Journal: J Gen Intern Med Date: 2013-07 Impact factor: 5.128
Authors: Karen M Goldstein; Karen M Stechuchak; Leah L Zullig; Eugene Z Oddone; Maren K Olsen; Felicia A McCant; Lori A Bastian; Bryan C Batch; Hayden B Bosworth Journal: J Womens Health (Larchmt) Date: 2017-02-13 Impact factor: 2.681
Authors: Dara H Sorkin; John Billimek; Kristin J August; Quyen Ngo-Metzger; Sherrie H Kaplan; Andrew R Reikes; Sheldon Greenfield Journal: Fam Pract Date: 2015-04-05 Impact factor: 2.267
Authors: Chloe E Bird; Marc N Elliott; John L Adams; Eric C Schneider; David J Klein; Jacob W Dembosky; Sarah Gaillot; Allen M Fremont; Amelia M Haviland Journal: J Gen Intern Med Date: 2018-08-10 Impact factor: 5.128
Authors: Eric K Broni; Chiadi E Ndumele; Justin B Echouffo-Tcheugui; Rita R Kalyani; Wendy L Bennett; Erin D Michos Journal: Curr Diab Rep Date: 2022-02-14 Impact factor: 4.810
Authors: Melawhy L Garcia; Sheila F Castañeda; Matthew A Allison; John P Elder; Gregory A Talavera Journal: Diabetes Res Clin Pract Date: 2019-04-04 Impact factor: 8.180
Authors: Timo Kauppila; Merja K Laine; Mikko Honkasalo; Marko Raina; Johan G Eriksson Journal: Scand J Prim Health Care Date: 2016-07-12 Impact factor: 2.581